Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly

Trial Profile

Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clopidogrel (Primary) ; Prasugrel; Ticagrelor
  • Indications Acute coronary syndromes; Myocardial infarction; Stroke; Unstable angina pectoris
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms POPular-AGE
  • Most Recent Events

    • 01 Jul 2021 Results of a pre-specified sub analysis (n=991) from the POPular Genetics and POPular Age trials assessing the effect of CYP2C19 loss-of-function alleles in clopidogrel treated elderly patients, published in the International Journal of Cardiology.
    • 15 Sep 2020 Primary endpoint has been met. (Net clinical benefit at 1 year after randomisation)
    • 15 Sep 2020 Results published in the Annals of Internal Medicine
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top